The drugmaker announced a 27% increase in net profit for the 2025 financial year, reaching 5.56 billion yuan ($804 million), comfortably ahead of analyst forecasts compiled by LSEG. Revenue also saw strong momentum, climbing 22.6% year-on-year to 15.03 billion yuan.
Hansoh, which focuses on therapeutic areas such as oncology, central nervous system disorders, metabolic diseases, and autoimmune conditions, has increasingly shifted its strategy toward innovation and global partnerships. This transition comes as China’s centralized bulk procurement policies continue to put pressure on margins for generic drug manufacturers.
A key driver of growth has been its expanding pipeline of innovative treatments and cross-border collaborations. In October, the company entered into a major licensing agreement worth up to $1.45 billion with Swiss pharmaceutical giant Roche for an investigational therapy targeting colorectal cancer and other solid tumours.
That deal forms part of a broader push by Hansoh to strengthen its international footprint. Over the past year, the company has also secured partnerships with global players including Glenmark Pharmaceuticals and Regeneron Pharmaceuticals, reflecting growing interest in its research capabilities and drug pipeline.
The company’s performance highlights a broader shift within China’s pharmaceutical sector, where firms are increasingly prioritizing innovation and overseas collaboration to offset domestic pricing pressures.
With a stronger emphasis on high-value therapies and strategic alliances, Hansoh appears well-positioned to sustain growth despite ongoing regulatory and pricing challenges in its home market.